Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 12/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5339506 | 0.84 | SMN1; SMN2 (0.46) | ARCYP19A1MEN1ALDH1A1LMNA | |
| SCHEMBL9889480 | 0.84 | AR (0.56) | ARMAOAMAOBALDH1A1TTR | |
| SCHEMBL3168191 | 0.83 | GAA (0.50) | ARMAOAMAOBCYP19A1MEN1 | |
| Fumaric Acid SCHEMBL6817583 | 0.83 | MAOA (0.40) | ARMAOAMAOBALDH1A1IMPDH2 | |
| Fumaric Acid SCHEMBL6817580 | 0.83 | MAOA (0.40) | ARMAOAMAOBALDH1A1IMPDH2 | |
| SCHEMBL6500894 | 0.79 | TTR (0.56) | ARMAOAMAOBMEN1ALDH1A1 | |
| SCHEMBL19243059 | 0.79 | MAOA (0.50) | MAOAMAOBMEN1ALDH1A1LMNA | |
| SCHEMBL7984102 | 0.79 | AR (0.56) | ARCYP19A1 | |
| SCHEMBL30185052 | 0.79 | CYP19A1 (0.54) | ARMAOAMAOBCYP19A1MEN1 | |
| SCHEMBL28686276 | 0.79 | CYP19A1 (0.54) | ARMAOAMAOBCYP19A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276528-B2 | Compounds for the inhibition of nitric oxide synthase | ASTRAZENECA AB (SE) | 2007-10-02 | — | — | US | disclosed |
| US-7119122-B2 | Compounds for the inhibition of nitric oxide synthase | ASTRAZENECA AB (SE) | 2006-10-10 | — | — | US | disclosed |
| US-20060217424-A1 | Nitro- or cyanopyridines substituted by an aminoalkylaryloxy- or aminoalkylarylethio- group, e.g., 2-(2-methoxy-3-methylaminomethyl-phenoxy)-6-trifluoromethyl-nicotinonitrile; treating rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, chronic obstructive pulmonary disease and pain | CONNOLLY STEPHEN | 2006-09-28 | — | — | US | disclosed |
| US-20040260088-A1 | 2,4-disubstituted benzonitriles or nitrobenzenes; nitric oxide synthase inhibitors; antiinflammatory agents, analgesics; central nervous system disorders, migraines | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | US | disclosed |
| EP-1434756-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003029185-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040260088-A1 | 2,4-disubstituted benzonitriles or nitrobenzenes; nitric oxide synthase inhibitors; antiinflammatory agents, analgesics; central nervous system disorders, migraines | NOS1, NOS3, NOS2 | AR 4088/4885MAOA 119/4885MAOB 18/4885 |
| US-20060217424-A1 | Nitro- or cyanopyridines substituted by an aminoalkylaryloxy- or aminoalkylarylethio- group, e.g., 2-(2-methoxy-3-methylaminomethyl-phenoxy)-6-trifluoromethyl-nicotinonitrile; treating rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, chronic obstructive pulmonary disease and pain | NOS3, NOS1, NOS2 | AR 3054/4885MAOA 549/4885MAOB 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.